Method
Level · gp.fundamentals.debt_to_revenue
Raw value 10591.59% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTMilestone Pharmaceuticals Inc.'s latest supported as-filed period reports revenue of $559,000. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 10591.59% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.65% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -4063.33% · OPTIONAL
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 844.72% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 94.28% · CORE
Level · gp.fundamentals.operating_margin
Raw value -4584.97% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Operating income changed -104.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -120.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
MIST · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-105052SEC ↗8-KAug 12, 2026Period Aug 12, 20260001104659-26-094466SEC ↗10-QAug 12, 2026Period Jun 30, 20260001104659-26-094435SEC ↗8-KJun 15, 2026Period Jun 10, 20260001104659-26-074025SEC ↗4Jun 12, 2026Period Jun 10, 20260001568850-26-000002SEC ↗4Jun 12, 2026Period Jun 10, 20260001573553-26-000002SEC ↗4Jun 12, 2026Period Jun 10, 20260001970274-26-000004SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 10, 2026Filed Jun 12, 2026 | Giles Lisa M.Director | Grant Or AwardDirect | 77,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 627.73% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 239.36% · OPTIONAL
Cash & equivalents changed +299.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Debt changed +7.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Research & development changed -4.4% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +2.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001634189-26-000002